Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Respiratory Syncytial Virus Vaccines | 2 | 2019 | 104 | 0.87 | Why? |
| Respiratory Syncytial Virus, Human | 3 | 2019 | 846 | 0.68 | Why? |
| Respiratory Syncytial Virus Infections | 3 | 2019 | 1234 | 0.57 | Why? |
| Drug Carriers | 1 | 2019 | 590 | 0.49 | Why? |
| Students, Medical | 2 | 2021 | 4032 | 0.44 | Why? |
| Microbiota | 2 | 2020 | 1240 | 0.42 | Why? |
| Immunity, Cellular | 1 | 2019 | 3614 | 0.30 | Why? |
| Immunization Schedule | 3 | 2021 | 1305 | 0.27 | Why? |
| Immunity, Humoral | 1 | 2019 | 4849 | 0.27 | Why? |
| Mastadenovirus | 1 | 2019 | 18 | 0.20 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.20 | Why? |
| Antibody-Producing Cells | 1 | 2019 | 66 | 0.19 | Why? |
| Vaccinia virus | 1 | 2019 | 346 | 0.16 | Why? |
| Clinical Deterioration | 1 | 2021 | 473 | 0.16 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.16 | Why? |
| Injections, Intramuscular | 1 | 2019 | 800 | 0.15 | Why? |
| Volunteers | 1 | 2021 | 601 | 0.14 | Why? |
| Administration, Intranasal | 1 | 2019 | 1132 | 0.14 | Why? |
| Healthy Volunteers | 1 | 2019 | 1444 | 0.12 | Why? |
| Immunization, Secondary | 1 | 2021 | 1649 | 0.12 | Why? |
| Single-Blind Method | 3 | 2021 | 1283 | 0.12 | Why? |
| Respiratory Mucosa | 1 | 2019 | 1522 | 0.10 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 1261 | 0.09 | Why? |
| Antibodies, Neutralizing | 3 | 2021 | 25288 | 0.09 | Why? |
| Clinical Decision-Making | 1 | 2021 | 3755 | 0.08 | Why? |
| State Medicine | 1 | 2020 | 2847 | 0.08 | Why? |
| Vaccines, Synthetic | 1 | 2019 | 3231 | 0.08 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.08 | Why? |
| Lymphocytes | 1 | 2018 | 3056 | 0.07 | Why? |
| Bacterial Infections | 1 | 2019 | 2229 | 0.07 | Why? |
| B-Lymphocytes | 1 | 2019 | 4418 | 0.07 | Why? |
| United Kingdom | 5 | 2021 | 18046 | 0.06 | Why? |
| Neutrophils | 1 | 2019 | 5476 | 0.06 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.06 | Why? |
| T-Lymphocytes | 1 | 2019 | 6670 | 0.06 | Why? |
| Equivalence Trials as Topic | 1 | 2021 | 242 | 0.05 | Why? |
| Adolescent | 6 | 2021 | 86841 | 0.05 | Why? |
| Young Adult | 6 | 2021 | 93724 | 0.05 | Why? |
| Intention to Treat Analysis | 1 | 2021 | 673 | 0.05 | Why? |
| Streptococcus | 1 | 2019 | 76 | 0.05 | Why? |
| Cell Degranulation | 1 | 2019 | 130 | 0.05 | Why? |
| Humans | 14 | 2021 | 930598 | 0.05 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.04 | Why? |
| Middle Aged | 9 | 2021 | 270681 | 0.04 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.04 | Why? |
| Serum | 1 | 2018 | 294 | 0.04 | Why? |
| Culture Media | 1 | 2018 | 366 | 0.04 | Why? |
| Fecal Microbiota Transplantation | 1 | 2021 | 372 | 0.04 | Why? |
| Aged | 7 | 2021 | 215776 | 0.04 | Why? |
| Kenya | 1 | 2019 | 887 | 0.04 | Why? |
| Male | 8 | 2021 | 367725 | 0.03 | Why? |
| Adult | 6 | 2021 | 244371 | 0.03 | Why? |
| Female | 8 | 2021 | 380317 | 0.03 | Why? |
| Metagenomics | 1 | 2019 | 823 | 0.03 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.03 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.03 | Why? |
| Nasal Mucosa | 1 | 2018 | 1218 | 0.03 | Why? |
| South Africa | 1 | 2020 | 3326 | 0.03 | Why? |
| Double-Blind Method | 1 | 2020 | 5988 | 0.02 | Why? |
| Retrospective Studies | 1 | 2021 | 105322 | 0.02 | Why? |
| Clinical Protocols | 1 | 2020 | 2734 | 0.02 | Why? |
| Infant, Newborn | 2 | 2020 | 23105 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Proteomics | 1 | 2019 | 2481 | 0.02 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.02 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.02 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.02 | Why? |
| Cells, Cultured | 1 | 2018 | 5835 | 0.02 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2021 | 3388 | 0.02 | Why? |
| Critical Care | 2 | 2021 | 14081 | 0.02 | Why? |
| Infant | 2 | 2020 | 30274 | 0.02 | Why? |
| Hospital Mortality | 2 | 2021 | 22087 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.02 | Why? |
| Survival Rate | 1 | 2020 | 9206 | 0.02 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.02 | Why? |
| Child, Preschool | 2 | 2020 | 36283 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Neutralization Tests | 1 | 2018 | 6698 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2021 | 11304 | 0.02 | Why? |
| Patient Admission | 1 | 2021 | 5250 | 0.02 | Why? |
| Brazil | 1 | 2020 | 12582 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 7868 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| Asymptomatic Infections | 1 | 2021 | 7218 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2021 | 10649 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 11367 | 0.01 | Why? |
| Viral Load | 1 | 2021 | 15850 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
| Cohort Studies | 1 | 2020 | 36005 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |
| Risk Factors | 1 | 2020 | 71621 | 0.01 | Why? |
| Child | 1 | 2020 | 70012 | 0.01 | Why? |